hexarelin for fat loss: Frequently asked questions

Hexarelin will still elevate growth hormone and mobilize free fatty acids into circulation, but those fatty acids must be oxidized through energy expenditure to produce net fat loss. If caloric intake matches or exceeds total daily energy expenditure (TDEE), the mobilized fatty acids will be re-esterified and stored in adipose tissue rather than burned for fuel. Growth hormone creates a permissive metabolic environment for lipolysis, but it does not override thermodynamics. Fat oxidation requires a negative energy balance. Research in growth hormone-deficient adults shows that GH replacement without dietary modification produces minimal fat loss despite normalized GH levels, confirming that the hormone facilitates but does not independently drive adipose reduction.

Symptoms such as gynecomastia, libido suppression, or lactation (in females) indicate that prolactin elevation has exceeded physiological tolerance. Discontinue hexarelin immediately and transition to a more selective GH secretagogue like Ipamorelin, which produces less than 10% prolactin elevation at therapeutic doses. In research settings, dopamine agonists such as cabergoline (0.25–0.5 mg twice weekly) are used to suppress prolactin when GH secretagogue protocols cannot be interrupted, but this introduces additional pharmacological complexity and should only be undertaken under medical supervision. Hexarelin's prolactin response is dose-dependent. Reducing dose to 1 mcg/kg or less may eliminate symptoms while preserving partial GH benefit.

You are likely experiencing GHSR-1a receptor desensitization, a well-documented phenomenon where chronic agonist exposure downregulates receptor density and responsiveness. The solution is a washout period. Discontinue hexarelin for 2–4 weeks to allow receptor upregulation, then resume at the original dose. Alternatively, rotate to a different GH secretagogue like Ipamorelin or GHRP-2 during the washout phase to maintain GH output through a different receptor activation pattern. Some protocols use hexarelin for 4–6 weeks at maximum intensity, then switch to ipamorelin for 8–12 weeks of maintenance, cycling back to hexarelin only when aggressive fat loss is again prioritized.

Use GHRP-2 or Ipamorelin as comparators—both are GHSR-1a agonists with slightly different receptor kinetics, making them mechanistically comparable. GHRP-2 produces stronger GH pulses but may increase cortisol and prolactin at higher doses, while Ipamorelin is more selective for GH without affecting other pituitary hormones. Hexarelin sits between the two in terms of GH pulse magnitude and selectivity. Run parallel treatment groups with identical dosing schedules and measure GH peak response, adipose tissue mass change, and circulating free fatty acids. That design isolates receptor-binding differences without introducing confounding variables like different administration routes or timing.

Verify peptide purity and storage integrity first—request a certificate of analysis and confirm the peptide was stored at −20°C before reconstitution and 2–8°C after. A temperature excursion during shipping or storage can degrade binding affinity by 30–60%, rendering the peptide ineffective. If purity is confirmed, evaluate dosing timing: Hexarelin administered post-meal or during elevated insulin states will not activate lipolysis effectively because insulin antagonizes hormone-sensitive lipase. Shift dosing to fasted state (morning or late evening) and re-run the protocol. If results remain null, check for GHSR-1a receptor polymorphisms in your model—some rodent strains express lower receptor density, which reduces GH response to secretagogues.

Don't. Reconstituted peptides degrade through hydrolysis and oxidation regardless of refrigeration—by day 28, binding affinity has dropped 30–40%, and by day 42, the peptide is no longer reliable for controlled research. If your study requires dosing beyond 28 days, reconstitute smaller aliquots and keep additional vials lyophilized at −20°C. Lyophilized peptides remain stable for 12–24 months under proper storage, but once water is introduced, the degradation clock starts immediately. Extending reconstituted peptide storage beyond manufacturer guidelines introduces a confounding variable that invalidates dose consistency.

Water retention (peripheral oedema, bloating) occurs in approximately 10–15% of research models and results from GH-induced sodium retention in renal tubules. It's dose-dependent: higher doses (300mcg+ per injection) increase aldosterone co-secretion. Reduce dose to 100–150mcg per injection and increase hydration to 3+ litres daily. Paradoxically, drinking more water reduces retention by diluting plasma aldosterone. If retention persists, discontinue for 48 hours to allow renal clearance, then resume at lower dose. Persistent oedema beyond 72 hours post-cessation is uncommon and warrants discontinuation.

GH pulse amplitude drops by 40–60% when administered within 2 hours of eating. Elevated blood glucose triggers insulin secretion, which activates somatostatin. A hypothalamic hormone that directly inhibits GH release from pituitary somatotrophs. The Hexarelin still binds ghrelin receptors correctly, but downstream signalling is blunted. If you've already injected post-meal, the dose isn't wasted entirely. You'll see a smaller GH elevation. But it's suboptimal. For maximum lipolytic effect, administer only during fasted windows: immediately upon waking or at least 3 hours after lunch.

Missing a single dose has negligible impact on cumulative GH exposure over a 4–6 week cycle. Resume your normal schedule at the next planned injection. Do not double-dose to compensate. Doubling doses increases cortisol co-release without proportional GH benefit and accelerates receptor desensitisation. If you miss an entire day (both morning and evening doses), simply continue the cycle as planned. Missing 3+ consecutive days may justify extending the cycle by those days to maintain total peptide exposure, but this is optional.